Investigators used CRISPR/Cas9-based genome editing to generate a mouse model that was deficient of all monocyte chemoattractant proteins, and used this strain to effectively abolish monocyte infiltration in genetically engineered murine models of de novo glioblastoma and hepatocellular carcinoma.
[Nature Communications]